Loading
TT
TCR2 Therapeutics Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 30 May 2023.
TCR2 Therapeutics Inc.: what insiders have been doing
Every trade that managers of TCR2 Therapeutics Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector. No insider at TCR2 Therapeutics Inc. has published a filing in the past twelve months. The most recent one dates from 14 February 2024.
These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
37
Thresholds
n/a
Buy Volume
€281,616
4 ops. · all time
Sell Volume
€61,715
16 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2022FY ended December 2022 · cache
Income statement
Net income-US$130.7M
Last declaration on 14 February 2024
Declarations37 total
4,394,800 sharesCommon StockSEC:0001415889-24-003784:0
3,370,982 shares0Common StockSEC:0001209191-23-034346:0
4,158,964 shares0Common StockSEC:0001209191-23-034340:0
4,158,964 shares0Common StockSEC:0001209191-23-034343:0
304,001 shares0Common StockSEC:0001209191-23-034336:0
132,729 sharesCommon StockSEC:0001104659-23-067053:0
109,459 sharesCommon StockSEC:0001104659-23-067068:0
48,745 sharesCommon StockSEC:0001104659-23-067051:0
24,092 sharesCommon StockSEC:0001104659-23-067064:0
50,000 shares@ US$1.7228.5% of flowCommon StockSEC:0001209191-23-033041:0
Canonical exit: 23 Aug 2023 (T+90)
178,269 shares@ US$0.74100.0% of flowCommon StockSEC:0001209191-23-031888:0
178,269 shares@ US$0.74100.0% of flowCommon StockSEC:0001209191-23-031889:0
38,765 shares@ US$1.9524.6% of flowCommon StockSEC:0001209191-23-029527:0
Canonical exit: 9 Aug 2023 (T+90)
57,073 shares@ US$1.9535.9% of flowCommon StockSEC:0001209191-23-028565:0
Canonical exit: 6 Aug 2023 (T+90)
18,513 shares@ US$1.8511.0% of flowCommon StockSEC:0001209191-23-027833:0
Canonical exit: 1 Aug 2023 (T+90)
2,792 shares@ US$1.12813.1% of flowCommon StockSEC:0000899243-22-038381:0
1,561 shares@ US$1.13133.2% of flowCommon StockSEC:0000899243-22-038384:0
10,325 shares@ US$1.13123.8% of flowCommon StockSEC:0000899243-22-038380:0
4,461 shares@ US$1.1326.0% of flowCommon StockSEC:0000899243-22-038387:0
3,928 shares@ US$1.28326.3% of flowCommon StockSEC:0000899243-22-038102:0
1,378 shares@ US$1.28233.5% of flowCommon StockSEC:0000899243-22-038096:0
2,457 shares@ US$1.28213.2% of flowCommon StockSEC:0000899243-22-038097:0
9,111 shares@ US$1.28224.0% of flowCommon StockSEC:0000899243-22-038098:0
2,302 shares@ US$1.37313.2% of flowCommon StockSEC:0000899243-22-037940:0
8,530 shares@ US$1.37223.9% of flowCommon StockSEC:0000899243-22-037941:0
25 of 37 declarations
About TCR2 Therapeutics Inc.
TCR2 Therapeutics Inc. was a U.S.-based biotechnology company listed on NASDAQ in the United States, focused on next-generation cell therapy and immunotherapy for solid tumors. Built during the rapid expansion of engineered T-cell science, the company positioned itself as a clinical-stage developer of novel T-cell therapies designed to recognize tumor-associated antigens. Its headquarters were in Cambridge, Massachusetts, placing it in one of the most important biotech clusters in the U.S. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1750019/000095017023009312/tcrr-20221231.htm?utm_source=openai))
From an operating standpoint, TCR2 was not a commercial-stage company. It was primarily a research and development organization, with value creation tied to its clinical pipeline, translational data, and regulatory progress rather than to product sales. Its strategy centered on engineered T-cell approaches for solid tumors, a therapeutic area that remains more difficult than hematologic cancers because of tumor heterogeneity, the tumor microenvironment, and the challenge of achieving durable responses. In practical equity-analysis terms, the company should be viewed as a pipeline-driven biotech whose valuation depended on clinical milestones, capital access, and strategic partnering. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1750019/000095017023009312/tcrr-20221231.htm?utm_source=openai))
Read moreShow less
Competitively, TCR2 operated in a crowded and highly innovative field that included larger biotech groups and many small-cap cell therapy developers. Its differentiation came from its focus on antigen-specific T-cell engagement in solid tumors and on advancing programs intended to address high unmet medical need. The company’s business model was therefore typical of an early-to-mid-stage biotech: no meaningful commercial product base, high R&D intensity, and significant binary risk around trial outcomes. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1750019/000095017023009312/tcrr-20221231.htm?utm_source=openai))
A major corporate event reshaped the story. In March 2023, TCR2 announced an all-stock strategic combination with Adaptimmune Therapeutics plc, and the merger closed on June 1, 2023. That transaction effectively ended TCR2’s life as an independent public company and integrated its assets into Adaptimmune’s broader solid-tumor cell therapy platform. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1750019/000110465923030597/tm238549d4_425.htm?utm_source=openai))
For investors analyzing SEC Form 4 insider activity today, TCR2 is best understood as a historical issuer rather than an active standalone listed name. The most relevant takeaways are its former status as a NASDAQ-listed U.S. biotech, its Cambridge, Massachusetts base, its focus on engineered T-cell therapies for solid tumors, and the significance of the 2023 merger, which consolidated the company into Adaptimmune. ([adaptimmune.com](https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/247/adaptimmune-announces-completion-of-strategic-combination?utm_source=openai))
